gamma-hydroxy-gamma-ethyl-gamma-phenylbutyramide has been researched along with Schistosoma mansoni Infection in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alter, G; Bagaya, BS; Balungi, P; Bartsch, Y; Biribawa, VM; Canderan, G; Connors, J; Corstjens, PLAM; de Dood, CJ; Elliott, AM; Fast, P; Fourati, S; Haddad, EK; Kaleebu, P; Kamali, A; Kitandwe, PK; Kiwanuka, N; Kyosiimire-Lugemwa, J; Mayanja, Y; Metcalf, T; Mpendo, J; Muir, R; Muyanja, E; Namara, I; Namatovu, T; Namuniina, A; Nanvubya, A; Nassuna, J; Odongo, M; Okech, B; Price, MA; Sekaly, RP; Senyonga, W; Ssetaala, A; van Dam, GJ | 1 |
1 other study(ies) available for gamma-hydroxy-gamma-ethyl-gamma-phenylbutyramide and Schistosoma mansoni Infection
| Article | Year |
|---|---|
Schistosoma mansoni infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses.
Topics: Animals; Antigens, Helminth; Cytokines; Immunity; Schistosoma mansoni; Schistosomiasis mansoni; Vaccination | 2023 |